$58.45
-0.05(-0.09%)
Mkt Cap $8.4B
$28.04
$63.04
52-Week Range
At A Glance
1
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
2
Most recently: and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc (2026-02-24).
$8.4B
Market Cap
—
Revenue
-$811M
Net Income
Employees414
Fundamentals
How The Business Makes Money
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001649094
ISINUS92243G1085
CUSIP92243G108
Phone650 837 0111
Address825 Industrial Road, San Carlos, CA, 94070, US
SEC EDGAR